Killing of Brain Tumor Cells by Hypoxia-Responsive Element Mediated Expression of BAX

Neoplasia

Volumn 1, Issue 5, 1999, Pages 431-437

  Ruan, Hangjun ^a   Wang, Jingli ^a   Hu, Lily ^a   Lin, Ching Shwun ^a   Lamborn, Kathleen R ^a   Deen, Dennis F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BAX; Brain tumor cells; Hypoxia; Hypoxia responsive element; Suicide gene

Indexed keywords

BAX PROTEIN, HUMAN; BETA GALACTOSIDASE; DNA BINDING PROTEIN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; NUCLEAR PROTEIN; ONCOPROTEIN; OXYGEN; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR;

ANOXIA; ARTICLE; BIOSYNTHESIS; BRAIN TUMOR; CELL CULTURE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; GLIOMA; HUMAN; LACTOSE OPERON; METABOLISM; NICK END LABELING; PLASMID;

ANOXIA; BCL-2-ASSOCIATED X PROTEIN; BETA-GALACTOSIDASE; BRAIN NEOPLASMS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IN SITU NICK-END LABELING; LAC OPERON; LUCIFERASES; NUCLEAR PROTEINS; OXYGEN; PLASMIDS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033222349     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900059     Document Type: Article

References (37)

1. Walker MD, Alexander EJ, Hunt WE, MacCarty CS, Mahaley MS, Mealey JJ, Norell HA, Owens G, Ransohoff J, and Wilson CB (1978). Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49, 333-343.
2. Walker MD, Strike TA, and Sheline GE (1979). An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5, 1725-1731.
3. Kayama T, Yoshimoto T, Fujimoto S, and Sakurai Y (1991). Intratumoral oxygen pressure in malignant brain tumor. J Neurosurg 74, 55-59.
4. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29, 427-431.
5. Vaupel P, Kallinowski F, and Okunieff P (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49, 6449-6465.
6. Brown JM (1979). Evidence for acutely hypoxic cells in mouse tumors and a possible mechanism for reoxygenation. Br J Radiol 52, 650-656.
7. Chaplin DJ, Durand RE, and Olive PL (1986). Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 12, 1279-1282.
8. Hall EJ (1993). Radiobiology for the Radiologist. J.B. Lippincott Co., Philadelphia, PA.
9. Wouters BG, and Brown JM (1997). Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 147, 541-550.
10. Semenza GL (1998). Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med 131, 207-214.
11. Ratcliffe PJ, O'Rourke JF, Maxwell PH, and Pugh CW (1998). Oxygen sensing: hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 201, 1153-1162.
12. 2 tension. Proc Natl Acad Sci USA 92, 5510-5514.
13. 2 tension. Am J Physiol 271, C1172-C1180.
14. 2 homeostasis by hypoxia-inducible factor 1α. Genes & Dev 12, 149-162.
15. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, and Keshet E (1998). HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 394, 485-490.
16. Ryan HE, Lo J, and Johnson RS (1998). HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 17 3005-3015.
17. Hoffman EC, Reyes H, Chu F-F, Sander F, Conley LH, Brooks BA, and Hankinson O (1991). Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252, 954-958.
18. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, and Fujii-Kurijama Y (1997). A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94, 4273-4278.
19. Tian H, McKnight SL, and Russell DW (1997). Endothelial PAS domain protein 1 (EPAS 1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11, 72-82.
20. Swanson HI, Chan WK, and Bradfield CA (1995). DNA binding specificities and pairing rules of the Ah receptor, ARNT, and SIM proteins. J Biol Chem 270, 26292-26302.
21. Bunn HF, Gu J, Huang LE, Park J-W, and Zhu H (1998). Erythropoietin: a model system for studying oxygen-dependent gene regulation. J Exp Biol 201, 1197-1201.
22. Semenza GL, and Wang GL (1992). A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12, 5447-5454.
23. Hassouna I, Wickert H, Zimmermann M, and Gillardon F (1996). Increase in BAX expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice. Neurosci Lett 204, 85-88.
24. Pastorino JG, Chen S-T, Tafani M, Snyder JW, and Farber JL (1998). The overexpression of BAX produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 273, 7770-7775.
25. Yin C, Knudson CM, Korsmeyer SJ, and Van Dyke T (1997). BAX suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385, 637-640.
26. Adams JM, and Cory S (1998). The Bcl-2 protein family: arbitors of cell survival. Science 281, 1322-1326.
27. Green DR, and Reed JC (1998). Mitochondria and apoptosis. Science 281, 1309-1312.
28. Semenza GL, Nejfelt MK, Chi SM, and Antonarakis SE (1991). Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA 88, 5680-5684.
29. Thomlinson RH, and Gray LH (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9, 539-549.
30. Bremmer JC (1993). Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation. Cancer Metastasis Rev 12, 177-193.
31. Brown JM, and Giaccia AJ (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416.
32. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, and Harris AL (1997). Targeting gene expression to hypoxic tumor cells. Nat Med 3, 515-520.
33. Shibata T, Giaccia AJ, Laderoute KR, and Brown JM (1999). Tumor-specific gene therapy using hypoxia-responsive gene expression. Proc 90th Annu Meet Am Assoc Cancer Res 40, 632.
34. Forsythe JA, Jiang B, Iyer NV, Agani F, Leung SW, Koos RD, and Semenza GL (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16, 4604-4613.
35. Firth JD, Ebert BL, Pugh CW, and Ratcliffe PJ (1994). Oxygen regulated elements in the phosphoglycerate kinase-1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3′ enhancer. Proc Natl Acad Sci USA 91, 6496-6500.
36. Pope IM, Poston GJ, and Kinsella AR (1997). The role of the bystander effect in suicide gene therapy. Euro J Cancer 33, 1005-1016.
37. Gagandeep S, Brew R, Green B, Christmas SE, Klatzmann D, Poston J, and Kinsella AR (1996). Prodrug-activated gene therapy: involvement of an immunological component in the bystander effect. Cancer Gene Ther 3, 83-88.